Sponsored by Kalderos
The debate around payment for drug costs is not new. Federal drug discount programs, including the Medicaid Drug Rebate Program (“MDRP”) and 340B Drug Discount Program (“340B Program”), have been around for more than a quarter century. These programs have acted as a tool to reduce provider and payer costs, and act as a deterrent against drug price inflation.
Through a thorough analysis of more than 300,000 claims reviewed by more than 2,100 covered entities, the issue of duplicate and non-compliant MDRP and 340B Program discounts is emerging.
Download this whitepaper to learn more about this analysis and a new path forward to bringing transparency and integrity to two critical federal drug discount programs.